Dynavax Technologies | DVAX - Net Income


Dynavax Technologies reported $18.72M in Net Income for its fiscal quarter ending in June of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Adma Biologics USD 36.43M 2.21M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.53B 83M Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Dynavax Technologies USD 18.72M 114.82M Jun/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
Glaxosmithkline GBP 2.71B 1.27B Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
TG Therapeutics USD 390.9M 362.71M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025